Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Trial Profile

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium; Warfarin
  • Indications Atrial fibrillation; Decompensated heart failure
  • Focus Biomarker; Therapeutic Use
  • Acronyms ROAD HF-AF
  • Most Recent Events

    • 09 Jan 2019 Planned End Date changed from 31 Jan 2020 to 1 Jan 2020.
    • 09 Jan 2019 Planned primary completion date changed from 31 Dec 2019 to 1 Sep 2019.
    • 09 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top